Melanotan-1 and Melanotan-2 are both synthetic analogs of alpha-melanocyte-stimulating hormone, and the similar names hide two quite different molecules. One is a linear peptide the length of the native hormone. The other is a cyclic fragment less than half that size. This article compares them at the level a laboratory cares about: structure, receptor selectivity, stability and what each is used to model.
The parent molecule
Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin. It acts on the melanocortin receptor family, five G protein coupled receptors numbered MC1R through MC5R, and it is rapidly degraded in circulation. Both Melanotan compounds exist because researchers wanted the same receptor activity with a molecule that lasts longer than the native hormone does.
Melanotan-1: a linear analog with two substitutions
Melanotan-1, also called afamelanotide or NDP-alpha-MSH in the older literature, keeps the full thirteen-residue backbone of alpha-MSH and changes two positions. Methionine at position 4 is replaced with norleucine, written Nle4. Phenylalanine at position 7 is replaced with its D isomer, written D-Phe7.
Both changes are defensive. The methionine side chain carries a sulfur that oxidizes readily, and norleucine is a close structural match without that liability. The D-phenylalanine substitution blocks a site that peptidases recognize and also locks the local backbone geometry into the conformation the receptor prefers. The original 1980 report described the result as far more potent than the native hormone with a much longer duration of activity in the assays used, and that combination is why Melanotan-1 became a standard reference agonist in melanocortin work.
Melanotan-2: a cyclic heptapeptide
Melanotan-2 takes a different approach. Rather than keeping the full chain, it retains the core message sequence and closes it into a ring through a lactam bridge between a lysine and an aspartate side chain. The result is a cyclic seven-residue analog that still carries the Nle and D-Phe substitutions in the active core.
Cyclization does what the substitutions do, only more so. A ring has far fewer accessible conformations than a linear chain, so the molecule spends most of its time in the shape the receptor binds, and it presents no free termini for exopeptidases to attack. Melanotan-2 is the more constrained molecule of the two.
Receptor selectivity is where they diverge
This is the difference that decides which compound belongs in which experiment. In the published binding and functional work, Melanotan-1 behaves as a potent agonist with a profile weighted toward MC1R, the receptor expressed on melanocytes and the one associated with pigmentation biology in the literature. Melanotan-2 is described as a broadly non-selective melanocortin agonist, active at MC1R but also at MC3R, MC4R and MC5R. MC4R in particular is a central receptor studied in energy-balance and behavioral models, and MC2R, the adrenal receptor, is the one member of the family that neither analog engages meaningfully because it responds to a different fragment.
| Melanotan-1 | Melanotan-2 | |
|---|---|---|
| Backbone | Linear, 13 residues | Cyclic, 7 residues, lactam bridge |
| Key substitutions | Nle4, D-Phe7 | Nle and D-Phe retained in the core |
| Receptor profile in the literature | Potent, weighted toward MC1R | Broad across MC1R, MC3R, MC4R, MC5R |
| Conformational freedom | Flexible chain | Constrained ring |
| Usual research question | MC1R pharmacology and pigmentation pathways in cell models | Central melanocortin signaling where MC3R and MC4R are in play |
Where PT-141 fits
PT-141, also called bremelanotide, is the third molecule in this family and it descends directly from Melanotan-2. It is the deaminated metabolite of the cyclic analog, meaning the C-terminal amide has been replaced with a free acid. That single change shifts the profile: the published pharmacology describes PT-141 as retaining melanocortin receptor activity with emphasis on MC4R and much less MC1R activity than its parent. For a laboratory, PT-141 is the tool for isolating central MC4R signaling from the pigmentation-associated MC1R arm that Melanotan-2 also drives. Running the pair together is a common way to separate the two.
Stability and handling
- Cyclic beats linear in solution. The lactam-bridged analog has no free termini and fewer accessible conformations, which makes it the more robust of the two once reconstituted.
- Both are lyophilized and both are light sensitive once dissolved. Amber storage or foil wrapping is standard practice for melanocortin analogs in solution.
- Norleucine removed the oxidation liability, not every liability. The tryptophan residue in the linear analog is still oxidizable, so freeze-thaw cycling is worth avoiding.
- Solutions are typically clear and colorless. A yellow tint in a reconstituted melanocortin analog is a reason to note the lot and check the certificate.
General handling rules for both are in our storage and stability guide, and terms such as lactam bridge, D-amino acid and agonist are defined in the research glossary. The background on why analogs are built this way at all is in what is a peptide. Both compounds sit in the broader peptide catalog.
Choosing between them
If the model is about MC1R and the readout is pigment biology in cells, the linear analog is the cleaner probe. If the question involves central melanocortin receptors, the cyclic analog reaches them. If the goal is MC4R specifically, with MC1R activity treated as a confound to be minimized, the MT-2 derived analog is the more selective choice. Comparing all three in one series is also informative, because the differences between them are structural and well documented rather than incidental.
Frequently asked questions
Are Melanotan-1 and Melanotan-2 the same peptide at different strengths?
No. They are different molecules. One is a linear thirteen-residue chain, the other a cyclic seven-residue ring, and their receptor selectivity profiles differ accordingly. Mass alone does not translate between them.
Why does cyclization change activity and not just stability?
Because a ring restricts which shapes the molecule can adopt. That both protects it from enzymes and biases it toward, or away from, the conformation each receptor subtype recognizes. Stability and selectivity come from the same structural change.
Which of the three is most selective?
In the published pharmacology the MT-2 derived analog PT-141 is the most MC4R-weighted, Melanotan-1 is the most MC1R-weighted, and Melanotan-2 is the least selective of the three.
References
- Sawyer TK, et al. 1980. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences.
- Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. 1989. Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamic simulations. Journal of the American Chemical Society.
- Hadley ME, Dorr RT. 2006. Melanocortin peptide therapeutics: historical milestones. Peptides.
- Gantz I, Fong TM. 2003. The melanocortin system. American Journal of Physiology: Endocrinology and Metabolism.
- Molinoff PB, et al. 2003. PT-141: a melanocortin agonist. Annals of the New York Academy of Sciences.
Research use only. Everything above describes laboratory and preclinical research. Homegrown Peptides products are not for human or animal use, are not drugs, are not cosmetics, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice or a protocol.
